Slide 1: LifeMD Investor Presentation August 2023
LifemD’ Investor Presentation August 2023 NASDAQ: LFMD Lifemo* ‘Schedule your appointment Today | Tomorrow Anyavaiobe provider Possible conditions: Middle ear infection Strong evidence
Slide 2: Important cautions regarding forward-looking statements
Important cautions regarding forward-looking statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21€ of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private
Slide 3: Building the leading platform for comprehensive virtual healthcare
Building the leading platform for comprehensive virtual healthcare © End-to-end, compliance-first platform for direct-to- consumer virtual primary care © Early-mover advantage and partnership strategy create a deep competitive moat © Affiliated 50-state medical group anchored by full-time providers
Slide 4: Investment highlights
Investment highlights Proven ability to operate at scale within large and growing addressable markets thanks to robust infrastructure Differentiated, end-to-end technology platform and affiliated medical group supporting complex virtual primary care needs of ~750 new patients per day Significant gro
Slide 5: Telehealth can solve many of the biggest problems facing the U.S. healthcare system
Telehealth can solve many of the biggest problems facing the U.S. healthcare system aS US.ol Armcatcens clon neve apprinay cero costet Hi a. espa, ho ynsdtem tne fiom conoduling Ho ibe Timeliness and the average wait time to see a family doctor is 20.6 days.’ first provider appointment is only 2 hou
Slide 6: A $170 billion total addressable market in the U.S.
A $170 billion total addressable market in the U.S. LifeMD's virtual care platform is addressing unmet needs in primary care and specialized healthcare. Male and Female Sexual Health Weight Management Diabetes Management Cardiovascular Health oS) Insomnia 2g Integrative Health & Wellness 8 —— #B Der
Slide 7: LifeMD has built an end-to-end platform for comprehensive virtual healthcare
LifeMD has built an end-to-end platform for comprehensive virtual healthcare Patient Acqui: Internal creative, online/offline media buying, SEO, and CRM platform Diagnostics Integrations with Quest & LabCorp and in-home collection Business Intelligence Data & analytics platform to drive compliance,
Slide 8: Technology designed to provide best-in-class care for all stakeholders
Technology designed to provide Best-in-class expe care for all stakeholders For Patients Patients benefit from an intuitive virtual care platform powered by a 50-state provider network, lab work partnerships, mail order pharmacy, and Al-powered tools. For Providers Streamlined workflow optimization
Slide 9: Our affiliated medical group, staffed by full-time providers, is central to our success
Our affiliated medical group, staffed by full-time providers, is central to our success 99% Of consults start on time* 98% Patients satisfied with their care 750K Consults completed State coverage 50 within 2 mi 200+ Different conditions LifeMD treats Dr. Gupta LifeMD Affiliated Provider “L love wha
Slide 10: Our success is driven by three core pillars
Our success is driven by three core pillars DTC Telemedicine © Subscription-based treatment + Rx Offerings © Established, wholly-owned brands with large customer base © Supported by mail order pharmacy capabilities © ED., pain, dermatology, insomnia, allergy & asthma Virtual Primary Care Services in
Slide 11: Our track record of strategic focus and growth
" Our track record of strategic focus and growth JUNE JUNE NOVEMBER JUNE ‘Acquired cloud - Commenced tech build Launched Launched GLP-1 based telehealth for LifeMD Virtual Primary VPC Platform “offering on VPC. technology platform Care {VPC) platform platfor FEBRUARY AUGUST. 2016-2019 DECEMBER Chang
Slide 12: Clear strategy focused on scaling high-value revenue streams
12 Clear strategy focused on scaling high-value revenue streams Key Priorities ra Continue to scale weight management/GLP-1 offering 5 Launch cardiovascular health and hormone therapy offerings < Launch commercial health insurance programs in 10 states é Prepare Medicare/Medicaid infrastructure for
Slide 13: WorkSimpli Software is rapidly growing and highly profitable
13 WorkSimpli Software is rapidly growing and highly profitable © Rapidly growing, global provider of Workplace and document Software-as-a-Service offerings to consumers and small businesses specializing in the pdf, resume/ HR, digital signature and forms markets © Over 170,000 subscribers with plat
Slide 14: Our management team has deep experience leading innovative healthcare organizations
4 Our management team has deep experience leading innovative healthcare organizations Justin Schreiber Chief Executive Officer & Chaiernan Marc Benathen Chief Financial Officer EQUINOX . blink ANN TAYLOR Jessica Friedeman 2 Eric Yecies Chief Marketing Officer General Counsel & Chief Compliance Offic
Slide 15: Our businesses have experienced rapid, consecutive YoY growth
. ° . $146-$152M Our businesses have experienced rapid, consecutive YoY Growth $119M $146M - $152M 2023E Revenue Forecast $93M $36M $25M 23% - 28% YoY Estimated Revenue $97M Growth in ‘23 $37M oon $7M 755K+ St3M som [eee Patients & Customers. i siim fi To-Date 2019 2020A 2021A 20224 2023 © Telehealt
Slide 16: Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 '22
16 Rapid growth in profitability after achieving adjusted EBITDA profit in Q4 ‘22 Annual consolidated adjusted EBITDA ($ millions) $10-$13M 2023E $(15)M 2022A 20214 Note: Consolidated adjusted EBITDA includes Telehealth and WorkSimpli results. Lifemot
Slide 17: Rapidly expanding gross margins and increasing leverage on marketing spend
"7 Rapidly expanding gross margins and increasing leverage on marketing spend driving continued growth in profitability Consolidated Gross Margin % Marketing Expenses as % of Net Revenue 90% 125% 35 88% a 100% 86% 3 2 75% 72% = ria 75% ae w | 84% Q 2 or Bo som 3 2 80% | 2 2a 25% 78% 122 c22m2 or2m2
Slide 18: Full year 2023 guidance reflecting substantial profitability growth
Full year 2023 guidance reflecting substantial profitability growth Consolidated Net Revenue Gross Margin % Consolidated Adj. EBITDA Free Cash Flow Break- Even FY 2023 GUIDANCE FY 2022 ACTUAL DELTA $146 - $152 million $119 million +23 - 28% 87% 84% +300 bps $10-$13 million $(15) million +25 to $28 m
Slide 19: Strong liquidity to meet our capital and growth needs
19 Strong liquidity to meet our capital and growth needs FY 2023 CASH FLOW GUIDANCE End of Year 2022 Actual Cash Balance $4 million Plus Avenue Capital FY23 Debt Proceeds, net +$18 million Operating Cash Flow (incl. Interest Expense) +$4-$8 million Less Capex $(6)-$(8) million Less Preferred Dividen
Slide 20: In summary
In summary © Significant presence within established and growing addressable markets © Proprietary technology platform differentiated by leading 50-state, affiliated physician network e High margin products/services generating 85%+ consolidated gross margins © Powerful telehealth infrastructure enab
Slide 21: LifeMD
LifeMD’ Company Contact Marc Benathen marc@lifemd.com Media Contact press@lifemd.com